These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 22939006)
41. Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder. Kellner M; Wiedemann K; Yassouridis A; Levengood R; Guo LS; Holsboer F; Yehuda R Biol Psychiatry; 2000 Jan; 47(2):107-11. PubMed ID: 10664826 [TBL] [Abstract][Full Text] [Related]
42. Increased brain serotonin turnover in panic disorder patients in the absence of a panic attack: reduction by a selective serotonin reuptake inhibitor. Esler M; Lambert E; Alvarenga M; Socratous F; Richards J; Barton D; Pier C; Brenchley C; Dawood T; Hastings J; Guo L; Haikerwal D; Kaye D; Jennings G; Kalff V; Kelly M; Wiesner G; Lambert G Stress; 2007 Aug; 10(3):295-304. PubMed ID: 17613943 [TBL] [Abstract][Full Text] [Related]
43. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder. Bradwejn J; Koszycki D; Annable L; Couëtoux du Tertre A; Reines S; Karkanias C Biol Psychiatry; 1992 Nov; 32(10):903-12. PubMed ID: 1467375 [TBL] [Abstract][Full Text] [Related]
44. Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers. Koszycki D; Cox BJ; Bradwejn J Am J Psychiatry; 1993 Dec; 150(12):1881-3. PubMed ID: 8238648 [TBL] [Abstract][Full Text] [Related]
45. Associations between personality traits and CCK-4-induced panic attacks in healthy volunteers. Tõru I; Aluoja A; Võhma U; Raag M; Vasar V; Maron E; Shlik J Psychiatry Res; 2010 Jul; 178(2):342-7. PubMed ID: 20471107 [TBL] [Abstract][Full Text] [Related]
46. The Effect of Escitalopram on Central Serotonergic and Dopaminergic Systems in Patients with Cervical Dystonia, and Its Relationship with Clinical Treatment Effects: A Double-Blind Placebo-Controlled Trial. Zoons E; Tijssen MAJ; Dreissen YEM; Smit M; Booij J Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32521736 [No Abstract] [Full Text] [Related]
47. The acute antipanic activity of aerobic exercise. Ströhle A; Feller C; Onken M; Godemann F; Heinz A; Dimeo F Am J Psychiatry; 2005 Dec; 162(12):2376-8. PubMed ID: 16330604 [TBL] [Abstract][Full Text] [Related]
48. The role of the beta-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms. Le Mellédo JM; Bradwejn J; Koszycki D; Bichet DG; Bellavance F Biol Psychiatry; 1998 Sep; 44(5):364-6. PubMed ID: 9755359 [TBL] [Abstract][Full Text] [Related]
49. Effects of citalopram and escitalopram on fMRI response to affective stimuli in healthy volunteers selected by serotonin transporter genotype. Henry ME; Lauriat TL; Lowen SB; Churchill JH; Hodgkinson CA; Goldman D; Renshaw PF Psychiatry Res; 2013 Sep; 213(3):217-24. PubMed ID: 23845563 [TBL] [Abstract][Full Text] [Related]
50. Sensitivity to cholecystokinin-tetrapeptide in major depression. Koszycki D; Copen J; Bradwejn J J Affect Disord; 2004 Jun; 80(2-3):285-90. PubMed ID: 15207943 [TBL] [Abstract][Full Text] [Related]
51. Chronic escitalopram in healthy volunteers has specific effects on reinforcement sensitivity: a double-blind, placebo-controlled semi-randomised study. Langley C; Armand S; Luo Q; Savulich G; Segerberg T; Søndergaard A; Pedersen EB; Svart N; Overgaard-Hansen O; Johansen A; Borgsted C; Cardinal RN; Robbins TW; Stenbæk DS; Knudsen GM; Sahakian BJ Neuropsychopharmacology; 2023 Mar; 48(4):664-670. PubMed ID: 36683090 [TBL] [Abstract][Full Text] [Related]